Pigmented progressive purpuric dermatosis - Pigmented Onitẹsiwaju Purpuric Dermatosishttps://en.wikipedia.org/wiki/Pigmented_purpuric_dermatosis
Pigmented Onitẹsiwaju Purpuric Dermatosis (Pigmented progressive purpuric dermatosis) n tọka si ipo awọ ti ko ni irẹwẹsi, ti a ṣe afihan nipasẹ awọn eruptions purpuric. Iwọn awọn ọgbẹ jẹ 0.3 si 1 cm, ti a maa n ri nigbagbogbo ni awọn apa isalẹ. Cortisone yoo ṣe iranlọwọ fun irẹwẹsi àti imudarasi awọ ara. Pigmented Onitẹsiwaju Purpuric Dermatosis (Pigmented progressive purpuric dermatosis) kò sí àwọn ààmì àìsàn míì lẹ́gbẹ̀ẹ́ awọ ara. Awọn ọgbẹ maa n han julọ lori awọn ẹsẹ isalẹ, ṣùgbọ́n ó lè wáyé ní ibikibi lórí ara, pẹ̀lú ọwọ, apa, torso, àti paapaa ọ̀run.

Itọju – Oògùn OTC
ikunra corticosteroid OTC
#Hydrocortisone ointment
#Hydrocortisone cream
☆ AI Dermatology — Free Service
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
  • Schamberg disease – Ọmọdekunrin ọdún 26 kan tí ó ní àpò pigmentiṣan àìlera àti telangiectasia lórí ẹsẹ̀.
    References Pigmented Purpuric Dermatoses: A Complete Narrative Review 34070260 
    NIH
    Pigmented purpuric dermatoses (PPD) jẹ ẹgbẹ kan ti awọn ipo awọ ara ti a samisi nipasẹ awọn agbegbe kekere ti ẹjẹ labẹ awọ ara nitori iredodo capillary. PPD maa n bẹrẹ bi pupa, lẹhinna awọn aaye yipada si goolu‑brown bi hemosiderin ti tun pada.
    Pigmented purpuric dermatoses (PPD) include several skin diseases characterized by multiple petechial hemorrhage as consequence of capillaritis. PPD generally present with red to purple macules that progressively evolve to golden-brown color as the hemosiderin is reabsorbed.
     Schamberg Disease 32809367 
    NIH
    Schamberg disease jẹ́ oríṣi tí ó wọ́pọ̀ jùlọ ti pigmented purpuric dermatoses (PPDs), èyí tí ó jẹ́ àìlera awọ‑ara oníbàjẹ́ tí ń hàn pupa tàbí àwọ̀ àlàáwọ̀ tó pọ̀ síi (àwọn àbùlé brown, pupa, tàbí ofeefee). PPD ti pín sí oríṣìí márùn‑ún: Schamberg's purpura, Majocchi purpura, lichen aureus, Gougerot‑Blum purpura, eczematoid‑like purpura of Doucas and Kapetanakis. Schamberg disease (SD) tún mọ̀ bí progressive pigmentary dermatosis of Schamberg, purpura pigmentosa progressiva, Schamberg's purpura. Ó máa ń kan àwọn ọkùnrin, ó sì ń hàn ní àwọn ẹsẹ ìsàlẹ̀, ṣùgbọ́n ó tún lè wáyé lórí àyà, àpòjú, ẹ̀hìn mọ́tò, tàbí àwọn àpá.
    Schamberg disease represents the most common type of pigmented purpuric dermatoses (PPDs), a chronic, benign, cutaneous eruptions characterized by petechiae, purpura, and increased skin pigmentation (brown, red, or yellow patchy). The PPDs are grouped into five clinical entities: Schamberg's purpura, Majocchi purpura, lichen aureus, Gougerot-Blum purpura and, eczematoid-like purpura of Doucas and Kapetanakis. Schamber disease (SD) has also been called: progressive pigmentary dermatosis of Schamberg, purpura pigmentosa progressive and, Schamberg's purpura. It is commonly seen in males and mainly affects the tibial regions, and could involve thighs, buttocks, trunk, or upper extremities.
     Characteristics and Clinical Manifestations of Pigmented Purpuric Dermatosis 26273156 
    NIH
    A ṣe atupale alaye lori awọn alaisan 113 tí ó ní PPD, pẹ̀lú 38 tí a ṣe biopsi awọ ara fún ìwádìí yìí. Iru àìlera tó wọ́pọ̀ jù lọ ni arun Schamberg (60.5%). Àwọn àìlera míì tó wà pẹ̀lú PPD ni haipatensonu (15.8%), diabetes (10.5%) àti àwọn míì. Ìtàn‑akọọlẹ oògùn fihan pé àwọn statins (13.2%), beta‑blockers (10.5%) àti àwọn míì. Àwọn àǹfààní tó lè ní í ṣe pẹ̀lú PPD ni ikọlu atẹ́gùn òkè tó ṣẹ̀ṣẹ̀ (5.3%), ìdúró gígùn tó yọrí sí titẹ orthostatic gíga (2.6%) àti adaṣe tó nira (2.6%). A ṣe itọju sí àwọn aláìsàn 36 (94.7%) pẹ̀lú oral antihistamines, pentoxifylline, topical steroids, àti/ tàbí phototherapy.
    Information on 113 patients with PPD was analyzed, and 38 subjects with skin biopsy were included for this study. Schamberg's disease was the most frequent clinical type (60.5%). Concomitant diseases included hypertension (15.8%), diabetes (10.5%), and others. Associated medication histories included statins (13.2%), beta blockers (10.5%), and others. Possibly associated etiologic factors were recent upper respiratory infection (5.3%), high orthostatic pressure due to prolonged standing (2.6%), and strenuous exercise (2.6%). A total of 36 patients (94.7%) were treated with one or more treatment methods, including oral antihistamines, pentoxifylline, topical steroids, and/or phototherapy.